Ovarian Cancer Has No Screening Test: Watch For These Warning Signs Instead

Ovarian cancer is often called a "silent disease" because it rarely announces itself clearly in its earliest stages. No major medical organization currently recommends routine screening for women at average risk — not because doctors haven't looked for a good test, but because the tests available (CA-125 blood work, transvaginal ultrasound) generate too many false alarms and unnecessary surgeries without actually saving more lives. Early detection, then, comes down almost entirely to recognizing symptoms and acting on them. The four symptoms worth knowing are persistent bloating, pelvic or abdominal pain, feeling full quickly, and urinary urgency. They're vague on their own, which is exactly the problem — but when one of them lingers for more than two to three weeks, it's worth a conversation with your doctor. The stakes are real: when ovarian cancer is caught while still confined to the ovary, roughly 92% of women are alive five years later. That number alone is why symptom awareness matters as much as it does.[1]

Emotional Introduction

Most of us grow up believing that early detection is simply a matter of showing up for the right test. A mammogram catches breast cancer early. A Pap smear catches cervical cancer early. So it comes as a genuine shock to learn that ovarian cancer has no equivalent — no routine blood test, no annual scan proven to catch it before it spreads.

That gap isn't a failure of modern medicine so much as a reflection of how quietly this disease behaves. This sits within the same proactive mindset covered in our Complete Guide to Preventive Gynecology. The ovaries sit deep in the pelvis, and a tumor can grow there for months before it presses against anything you'd notice. But here's the reassuring part: not having a screening test doesn't mean you're powerless. It means your own awareness becomes the frontline defense. Learn what your body is trying to tell you, take it seriously when it persists, and you give yourself the best chance at catching this early — the same chance a screening test would have offered, if one existed.

Understanding the Condition

Ovarian cancer starts when abnormal cells in the ovaries — or, as researchers now understand in many cases, in the fallopian tubes — begin dividing without the usual checks in place. The ovaries themselves are two small, almond-shaped organs on either side of the uterus, tasked with releasing eggs each month and producing estrogen and progesterone.

Because they sit deep in the pelvis, tumors there have room to grow quietly. There's no lump to feel, no obvious swelling to catch in a mirror, for a long time. By the time a tumor is large enough to cause real discomfort, it has often already spread beyond the ovary to the lining of the abdomen or nearby organs. According to the most recent data from the National Cancer Institute's SEER program, only about 22% of ovarian cancers are caught while still localized to the ovary. More than half — 54% — aren't found until the cancer has already spread to distant sites.[1] That single statistic explains almost everything else in this article: why symptom awareness matters so much, and why researchers have spent decades searching, unsuccessfully so far, for a screening test that actually works.

Anatomy & Physiology

The reproductive organs don't operate in isolation — they're tucked in among the bladder and intestines, all sharing the same tight space in the pelvis.

That proximity is precisely why ovarian cancer symptoms feel so much like something else. When an ovary swells because of a growing tumor, it physically pushes against the bladder or intestines nearby. The bloating, the urinary urgency, the sense of fullness after a few bites — these aren't random symptoms. They're the direct, mechanical result of one organ crowding its neighbors.

What Are the Early Warning Signs of Ovarian Cancer?

Ovarian cancer symptoms are frustratingly easy to write off. They mimic everyday indigestion, stress, or a normal hormonal fluctuation — which is exactly why so many women (and, frankly, so many doctors on a first visit) miss them. The one detail that separates a red flag from a passing nuisance is persistence.

A now-classic 2007 study by Goff and colleagues found that pelvic or abdominal pain, urinary urgency or frequency, increased abdominal size or bloating, and difficulty eating or early satiety were significantly linked to ovarian cancer — particularly when they'd been present for less than a year but occurred more than 12 days a month. That work became the foundation for what's known as the Goff Symptom Index, since refined and validated in multiple patient populations.[2]

One recent validation, a 2024 cross-sectional study of 150 symptomatic women in Pakistan, tested a Modified Goff Symptom Index and found it correctly flagged ovarian malignancy 86.3% of the time (sensitivity) while correctly ruling it out 80.7% of the time (specificity) — a strong result by diagnostic standards.[3] In that same study, the most common symptoms among women who turned out to have cancer were abdominal bloating (82%), early satiety (77%), pelvic pain (73%), and urinary urgency (59%).

Common warning symptoms

(worth a doctor's visit if they persist for more than two to three weeks)

• Persistent abdominal bloating or visible swelling
• Pelvic or abdominal pain that doesn't resolve
• Feeling full very quickly, or trouble eating (early satiety)
• Urgent or frequent need to urinate

Less common symptoms

• Unexplained fatigue
• Back pain
• New-onset constipation or other bowel changes
• Unexplained weight loss
• Pain during sex

Emergency symptoms — seek care immediately

• Sudden, severe abdominal pain
• Inability to keep food or fluids down
• Unexplained, heavy vaginal bleeding

Causes & Risk Factors

Nobody knows the single cause of ovarian cancer. What researchers have identified, though, is a set of factors that meaningfully raise or lower the odds.

Genetic and hereditary factors

Family history is, by a wide margin, the most significant risk factor. Up to a quarter of ovarian cancers trace back to an inherited cancer syndrome.[4]

Here's what that looks like in numbers. Women who inherit a harmful BRCA1 mutation face a 39–58% lifetime risk of ovarian cancer (a figure that also captures fallopian tube and primary peritoneal cancer, since these are now understood to share a common origin). A harmful BRCA2 mutation carries a 13–29% lifetime risk. Compare that to the general population, where lifetime risk sits at about 1.1%.[5] Harmful BRCA mutations themselves are uncommon — roughly 1 in 400 people carry one — but that frequency climbs sharply in certain populations; about 1 in 40 people of Ashkenazi Jewish descent carry one of a handful of founder mutations.

Other risk factors

• Age. Risk climbs steadily with age. Most cases are diagnosed after menopause, with a median diagnosis age in the early sixties.
• Reproductive history. Women who've never been pregnant, or who started menstruating early and reached menopause late, face a modestly higher risk — likely tied to a greater lifetime number of ovulations.
• Endometriosis. A large 2024 cohort study published in JAMA found that women with endometriosis had a 4.2-fold higher risk of ovarian cancer than women without it. For those with the more severe forms — deep infiltrating endometriosis or ovarian endometriomas — that risk climbed to roughly 9.7 times higher. The association was strongest for what are called "type I" ovarian cancers (clear cell and endometrioid subtypes), which also tend to be more surgically curable than other forms.[6] A separate genetic analysis, using a method called Mendelian randomization to test whether the link is truly causal rather than coincidental, found the same pattern: endometriosis was associated with roughly double the risk of clear cell ovarian cancer specifically.[7]
• Obesity. A higher body mass index has been linked to increased risk for certain ovarian cancer subtypes.

How Is Ovarian Cancer Diagnosed Without a Screening Test?

Since there's no test to run on a healthy, symptom-free woman, the diagnostic process only really begins once someone reports symptoms that won't quit.

It starts simply: a thorough history and a pelvic exam. If something feels off, the next step is usually a transvaginal ultrasound. If that reveals a mass, a doctor may order a CA-125 blood test, which measures a protein that tends to run high in women with ovarian cancer.

The catch is that CA-125 rises for plenty of reasons that have nothing to do with cancer — endometriosis and pelvic inflammatory disease among them — so it's used to support a diagnosis, never to confirm or rule one out on its own. The PLCO Cancer Screening Trial, discussed in more detail below, showed just how costly a false positive on these tests can be: unnecessary surgery, and the complications that sometimes come with it.[8]

There's better news on the diagnostic side, though. A 2024 analysis from the UK's ROCkeTS research programme looked at what happens when symptomatic women are fast-tracked through CA-125 and ultrasound testing rather than waiting on a routine referral. Among the women in that fast-track pathway who turned out to have high-grade serous ovarian cancer — the most common and aggressive subtype — just over a quarter (25.2%) were caught at an early stage (FIGO I/II), and 61.3% of those patients achieved complete surgical removal of visible cancer.[9] It's a strong argument for taking symptoms seriously and moving quickly, rather than a case for population-wide screening.

The only way to confirm ovarian cancer definitively is a surgical biopsy. If the earlier tests suggest a high likelihood of cancer, the next step is a referral to a gynecologic oncologist — a specialist trained specifically in these surgeries.

Treatment & Management

Treatment nearly always combines surgery with chemotherapy, and the exact approach depends heavily on how advanced the disease is at diagnosis and the patient's overall health.

Surgery

The surgical goal is called debulking, or cytoreductive surgery — removing as much visible cancer as possible. For early-stage disease, that might mean removing only the affected ovary and fallopian tube, preserving fertility where it's safe to do so. For more advanced disease, surgery typically becomes more extensive: both ovaries, both fallopian tubes, the uterus, nearby lymph nodes, and any visible tumor throughout the abdomen.

Chemotherapy

After surgery, most women receive chemotherapy to clear out microscopic cancer cells that surgery couldn't reach. This remains the backbone of treatment for the majority of ovarian cancer diagnoses.

PARP inhibitors

This is where treatment has changed the most in the last decade. PARP inhibitors work by exploiting a specific vulnerability in cancer cells that carry a BRCA mutation — their DNA repair machinery is already compromised, and blocking a second repair pathway (the one PARP enzymes handle) pushes those cells past what they can survive, a mechanism researchers call synthetic lethality.[10]

A 2024 systematic review pooling 16 randomized trials and nearly 5,800 patients found that PARP inhibitor maintenance therapy meaningfully improved progression-free survival — the length of time before the cancer grows or returns. In women newly diagnosed with advanced ovarian cancer, the overall population saw their risk of progression or death cut by more than half (hazard ratio 0.46), and that benefit was even larger in women with a BRCA mutation (hazard ratio 0.36). In recurrent disease, the effect was stronger still, with a hazard ratio of 0.34 in the total population.[11] Four PARP inhibitors currently carry FDA approval for BRCA-mutated ovarian cancer: olaparib, rucaparib, niraparib, and talazoparib.

It's worth being upfront about the limits here, too: that same 2024 review found no significant overall survival benefit from PARP inhibitors in a separate first-line meta-analysis, even though progression-free survival clearly improved — a reminder that living longer without the cancer growing isn't automatically the same as living longer overall, and that this remains an active, evolving area of research.[12]

Investigational therapies

Immunotherapy and new combination approaches for recurrent disease are being tested in ongoing clinical trials. None of these are yet standard of care, and where the evidence is still preliminary, it's worth saying so plainly rather than overselling early results.

Recovery & Self-Care

Recovery from ovarian cancer treatment isn't quick. Major abdominal surgery combined with chemotherapy asks a lot of the body, and patience matters as much as any single medical decision.

Small, frequent meals tend to sit better than large ones, especially while managing chemotherapy's effect on digestion. Movement — gentle, cleared by your care team, and increased gradually — helps counter the deep fatigue that chemotherapy brings. And the emotional weight of an ovarian cancer diagnosis is not a side note to recovery; it's part of it. Counseling, support groups, and leaning on family and friends aren't optional extras here. They're part of getting through this well.

Prevention

There's no guaranteed way to prevent ovarian cancer. But several factors are well established to meaningfully lower the odds.

Oral contraceptives

Few relationships in gynecologic oncology are as well documented as this one. A 2024 systematic review pooling 67 studies found that women who had ever used oral contraceptives had 31% lower odds of ovarian cancer than women who never had (pooled relative risk 0.69).[13] Protection builds with duration of use and, notably, doesn't disappear the moment someone stops taking the pill — earlier research has traced measurable protection out to decades after discontinuation. The National Cancer Institute summarizes the overall effect as roughly a 30–50% reduction in risk among those who've ever used oral contraceptives.

Pregnancy and breastfeeding

Pregnancy carries a protective effect as well. A large European cohort study (the EPIC study, following over 327,000 women) found that women who'd been pregnant had a 29% lower risk of ovarian cancer than those who hadn't, with roughly an 8% additional reduction for each further pregnancy.[14]

Risk-reducing surgery for high-risk women

For women confirmed to carry a BRCA mutation, risk-reducing salpingo-oophorectomy — surgical removal of the ovaries and fallopian tubes, typically recommended once childbearing is complete — offers the most powerful protection available. A landmark meta-analysis found this surgery associated with roughly a 79% reduction in ovarian and fallopian tube cancer risk, alongside a meaningful reduction in breast cancer risk as well.[15] A later prospective multicenter study confirmed that the surgery also reduces all-cause mortality among BRCA mutation carriers, not just cancer-specific risk.[16]

Myths vs. Facts

Scientific Evidence

The recommendation against routine ovarian cancer screening isn't a shrug — it's based on two of the largest randomized controlled trials ever run on the question.

UKCTOCS: the largest trial of its kind

The UK Collaborative Trial of Ovarian Cancer Screening followed 202,638 postmenopausal women for a median of 16.3 years — genuinely landmark in scale and duration. Women were randomly assigned to annual multimodal screening (CA-125 plus ultrasound as a second-line test), annual transvaginal ultrasound alone, or no screening at all.[17]

Multimodal screening did shift the stage at which cancers were caught: a 47.2% increase in stage I diagnoses and a 24.5% decrease in stage IV diagnoses compared with no screening. But that downstaging never translated into fewer deaths. There was no statistically significant reduction in ovarian or tubal cancer mortality in either screening group. As the trial's own investigators put it, given that screening didn't significantly reduce deaths, population-wide screening cannot be recommended.

PLCO: an earlier trial, a similar conclusion

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial reached a matching verdict a decade earlier. Among 39,105 women aged 55–74 screened annually with CA-125 and transvaginal ultrasound, screening did not reduce ovarian cancer mortality compared with usual care — and false-positive results led a meaningful number of women into surgery for conditions that turned out to be entirely benign.[8]

Together, these two trials are why "no screening test" isn't a gap doctors are ignoring. It's the honest conclusion of two of the best-designed studies medicine has ever run on the question.

Research Highlights

Never exaggerate findings; limitations are noted throughout the text above.

Clinical Perspective

At Dr. Dina Rezk Clinic, it's common for women — especially those with a family history of breast or ovarian cancer — to ask for a "screening ultrasound" simply for peace of mind. That instinct is completely understandable, and it's never dismissed. But the more useful conversation is usually a different one: a thorough risk assessment and an honest walk-through of what your body's normal actually feels like, so that a genuine change stands out clearly against that baseline. That's a better defense than any single unproven test could offer.

Related Conditions

• Ovarian cysts — fluid-filled sacs that are usually benign and often resolve on their own, though they can produce similar symptoms and occasionally raise CA-125.
• Endometriosis — tissue resembling the uterine lining growing outside the uterus, causing chronic pain and, as noted above, meaningfully raising ovarian cancer risk for certain subtypes.[6],[7]
• Irritable bowel syndrome (IBS) — a common digestive condition causing bloating and abdominal pain, frequently confused with early ovarian cancer symptoms. Persistence and frequency are the differentiators.
• Pelvic inflammatory disease (PID) — an infection of the reproductive organs that causes pelvic pain and can also raise CA-125.

Conclusion

Not having a screening test for ovarian cancer is a genuinely uncomfortable fact. But it doesn't leave you without options — it just changes what the best option is. Awareness of your own body, sustained over time, is the tool that actually works here. Don't wave off bloating that won't quit as "just a big meal." Don't write off pelvic pain as "just a cramp" once it outlasts your usual cycle. If a symptom is new, persistent beyond two to three weeks, and doesn't feel right, that's reason enough to ask for an evaluation.

The numbers make the case plainly. Caught while still localized, ovarian cancer has a five-year survival rate around 92%. Caught after it's spread to distant sites, that figure falls to roughly 31%.[1] Know your family history. Trust what your body is telling you. And don't hesitate to speak up — early evaluation is, quite literally, the only tool we currently have that saves lives.

This article discusses cancer risk and diagnosis, which can be a heavy topic for anyone currently navigating symptoms or a family history of the disease. If you're feeling anxious about your own risk, that's a completely normal response — and a conversation with your doctor is the most productive next step.

References

1. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Ovarian Cancer. Bethesda, MD: National Cancer Institute; 2026. Available at: https://seer.cancer.gov/statfacts/html/ovary.html
2. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221-227. DOI: 10.1002/cncr.22371.
3. Istafa L, Khan B, Wazir S, Maqsood SI, Musharaf M. Validation of the modified Goff Symptom Index for early detection of ovarian cancer in Pakistani women. Frontiers in Health Informatics. 2024;13(2):1151-1156.
4. American College of Obstetricians and Gynecologists. Hereditary Cancer Syndromes and Risk Assessment. ACOG Committee Opinion No. 793. Obstet Gynecol. 2019.
5. National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. Bethesda, MD: National Cancer Institute; 2024. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
6. Barnard ME, Farland LV, Yan B, et al. Endometriosis typology and ovarian cancer risk. JAMA. 2024;332(6):482-489. DOI: 10.1001/jama.2024.9210. PubMed: 39018030.
7. Zhang L, Yan H. Genetically identification of endometriosis and cancers risk in women through a two-sample Mendelian randomization study. Scientific Reports. 2024;14:8382. DOI: 10.1038/s41598-024-58950-7.
8. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-2303. DOI: 10.1001/jama.2011.766. PubMed: 21642681.
9. Kwong FLA, Kristunas C, Davenport C, et al. Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer. International Journal of Gynecological Cancer. 2024. DOI: 10.1136/ijgc-2024-005371.
10. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152-1158. DOI: 10.1126/science.aam7344.
11. Baradács I, Teutsch B, Váradi A, et al. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials. Journal of Ovarian Research. 2024;17(1):53. DOI: 10.1186/s13048-024-01362-y.
12. Petousis S, Kahramanoglu I, Appenzeller-Herzog C, et al. PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis. JAMA Network Open. 2025.
13. Arshadi M, Hesari E, Ahmadinezhad M, et al. The association between oral contraceptive pills and ovarian cancer risk: a systematic review and meta-analysis. Bulletin du Cancer. 2024;111(10):918-929. DOI: 10.1016/j.bulcan.2024.05.010. PubMed: 39261253.
14. European Prospective Investigation into Cancer and Nutrition (EPIC) Study Group. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer. 2012. DOI: 10.1038/bjc.2011.371.
15. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute. 2009;101(2):80-87. DOI: 10.1093/jnci/djn442. PubMed: 19141781.
16. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975. DOI: 10.1001/jama.2010.1237.
17. Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182-2193. DOI: 10.1016/S0140-6736(21)00731-5. PubMed: 33991479.